Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that mineralized nanocarriers reverse cholesterol metabolism and trigger ferroptosis in aggressive tumors, highlighting a potent strategy to enhance immunotherapy.
The occurrence and development of cancer are closely related to dysregulation of cholesterol metabolism. Therefore, targeting cholesterol metabolism presents a novel diagnosis and treatment strategy for cancer. In this study, a nanosystem (AVA-COD@Fe) exhibiting dual enzymatic activity was developed through a biomimetic mineralization approach. Cholesterol oxidase (COD) facilitated the consumption of cholesterol, thereby impairing the migratory capacity of tumor cells and diminishing resilience on oxidative stress. Concurrently, COD catalyzed the production of hydrogen peroxide (H₂O₂), which compensated for inadequate levels of tumor cells, thereby enhancing ferroptosis and ultimately inhibiting tumor growth and metastasis. Meanwhile, as an immune sensitizer, avasimibe altered cholesterol distribution, and promoted the infiltration and vitality of cytotoxic T lymphocytes into tumors jointly with immunogenic cell death (ICD) induced by ferroptosis, and enhanced anti-tumor immunity. To elicit significant immune memory effects, this nanosystem was further combined with the anti-programmed cell death protein ligand-1 antibody, which effectively inhibited the growth of both primary and metastatic tumors, and demonstrated a robust systemic anti-tumor immune response. This study addressed modulation of tumor cell cholesterol metabolism as a strategic entry point for tumor suppression, significantly curtailing tumor progression, and activating systemic immune responses, thereby offering a new perspective for future cancer therapies.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: